Humayou Ahmed

Dr. Humayou Ahmed


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
HAHumayou Ahmed
Humayou Ahmed
MKMuhammad Saad Khan
Muhammad Saad Khan
DZDaniyal Zulfiqar
Daniyal Zulfiqar
KMKainat Mehmood
Kainat Mehmood
KFKanza Farhan
Kanza Farhan
AWAminath Waafira
Aminath Waafira
Background: Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by isolated thrombocytopenia and increased bleeding risk. Although first-line therapies such as corticosteroids and intravenous immunoglobulin provide initial benefit, many patients relapse or develop refractory disease. Romiplostim, a thrombopoietin receptor agonist, has emerged as an effective second-line therapy; however, evidence comparing its efficacy and safety with placebo across both pediatric and adult populations remains limited. Methods: A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted following PRISMA guidelines (PROSPERO: CRD420261357179). PubMed, Scopus, Cochrane Library, and Google Scholar were searched up to March 2026. RCTs comparing romiplostim with placebo in ITP patients were included. A random-effects model was used to calculate mean differences (MD) and risk ratios (RR) with 95% confidence intervals (CI). Risk of bias was assessed using the Cochrane RoB 2 tool. Certainty of evidence was evaluated using the GRADE approach. Results: Nine RCTs (n=748) were included. Romiplostim significantly increased platelet counts at week 2 (MD 25.71; 95% CI 9.41–42.02), week 4 (MD 42.74; 95% CI 26.82–58.66), week 6 (MD 50.42; 95% CI 33.87–66.97), and week 8 (MD 49.14; 95% CI 20.45–77.83), with larger effects in adults. Platelet response rates were significantly higher with romiplostim (RR 6.10). The proportion achieving ≥20×10 9 /L increase improved (RR 3.23), and the need for rescue therapy decreased (RR 0.49). Adverse events were comparable between groups, with slight increases in myalgia and rash. Conclusion: Romiplostim is an effective and well-tolerated therapy for ITP, significantly improving platelet outcomes and reducing rescue therapy requirements without major safety concerns.

16 October 2026 in Clinical Case Reports
Verified
Journal Article
Open access
ASAhmed Ali Shaikh
Ahmed Ali Shaikh
FSFiza Shaikh
Fiza Shaikh
SASaad Arshad
Saad Arshad
TDTarachand Devrajani
Tarachand Devrajani
HAHumayou Ahmed
Humayou Ahmed
MAManal Al‐Dhaheri
Manal Al‐Dhaheri
Leptospirosis can masquerade as acute cholangitis with cholestatic jaundice, fever, and leukocytosis. In febrile patients with cholestatic liver profile without biliary obstruction, especially farmers with calf pain and conjunctival suffusion, consider leptospirosis early to initiate timely antibiotics and prevent poor outcomes.

9 October 2026 in Medicine
Verified
Journal Article
Open access
HAHumayou Ahmed
Humayou Ahmed
MKMuhammad Saad Khan
Muhammad Saad Khan
ZMZauha Fawad Memon
Zauha Fawad Memon
SBSerish Bano
Serish Bano
SSSamreen Shahid
Samreen Shahid
MAManal Al-Dhaheri
Manal Al-Dhaheri
Background: Cataract remains the leading cause of reversible blindness worldwide, particularly in low-resource settings. Effective control of postoperative inflammation is essential to prevent complications such as cystoid macular edema and raised intraocular pressure. Dexamethasone and Triamcinolone acetonide (TCA) are widely used corticosteroids; however, their comparative efficacy remains uncertain. This updated systematic review and meta-analysis aimed to compare their effectiveness following cataract surgery. Methods: A systematic search of 4 databases (PubMed, Google Scholar, Cochrane Central Library and Scopus) was conducted up to June 2026 following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (International Prospective Register of Systematic Reviews: CRD420261435380). Randomized controlled trials and prospective studies comparing dexamethasone and TCA in adults undergoing phacoemulsification were included. Risk of bias was assessed using cochrane risk of bias 2 and the Newcastle–Ottawa Scale. Certainty of evidence was evaluated using grading of recommendations assessment, development and evaluation. A random-effects model was used, with heterogeneity assessed by I 2 . Results: Twelve studies (nine randomized controlled trials and 3 non-randomized prospective studies; n = 2003) were included. No significant differences were observed in intraocular pressure (Mean Difference, mm Hg) at any time point up to 3 months. Visual acuity showed modest improvement with TCA at 7 and 28/30 days, though results were inconsistent on sensitivity analysis. No significant differences were found in anterior chamber flare or cells across all time points. A nonsignificant trend toward greater endothelial cell loss was observed with dexamethasone. Overall, evidence certainty was low. Conclusion: Dexamethasone and TCA demonstrate comparable efficacy and safety in controlling postoperative inflammation after cataract surgery. TCA may offer short-term visual benefits and prolonged action, whereas dexamethasone allows flexible dosing. Clinical decisions should be individualized, considering patient compliance and clinical context.

6 November 2026 in Langenbeck's Archives of Surgery
Verified
Journal Article
Open access
PDF file
HAHumayou Ahmed
Humayou Ahmed
AQAqsa
Aqsa
ESErum Siddiqui
Erum Siddiqui
KMKainat Mehmood
Kainat Mehmood
MHMaheen Hamid
Maheen Hamid
AMAbubakr Mahmoud
Abubakr Mahmoud
Background: The optimal management of medial epicondyle fractures remains controversial, particularly in displaced fracture without incarceration. Traditionally, non-surgical treatment remains the treatment of choice for the management of medial epicondyle fracture; however recent evidence suggesting favorable outcomes with surgical fixation has increased interest in operative management. This systematic review and meta-analysis aimed to compare surgical versus non-surgical treatment for the management of medial epicondyle fracture in pediatric population to determine the optimal management therapy. Methods: A systematic search of PubMed, Cochrane Library, and Google Scholar and Clinical trial govt. was conducted from inception to April 2026 according to PRISMA guidelines (PROSPERO: CRD420261393871 ) . Randomized controlled trials and observational studies were included. Statistical analyses were performed using a random-effects model in RevMan 5.4. Risk of bias was evaluated using the Cochrane RoB 2 tool and Newcastle–Ottawa Scale, while certainty of evidence was assessed using GRADE. Results: Six comparative studies involving 564 pediatric patients were included, comprising two randomized controlled trials and four cohort studies. Surgical fixation significantly reduced the risk of non-union (RR = 0.09, 95% CI: 0.02–0.39; p = 0.001) and worse cosmetic VAS scores (MD = − 8.56, 95% CI: −12.66 to − 4.46; p < 0.0001), favoring non-surgical management. However, surgery was associated with a significantly greater likelihood of requiring additional surgery (RR = 13.37, 95% CI: 5.20–34.35; p < 0.00001). No significant differences were observed between groups for DASH scores, elbow flexion or extension deficits, PedsQL scores, or valgus instability tests. Conclusion: Surgical treatment reduces nonunion but is associated with worse cosmetic outcomes in pediatric medial epicondyle fracture. However, its effect on functional outcomes remains uncertain compared with non-surgical treatment. Treatment decisions should therefore be individualized based on clinical and patient-specific factors.

4 September 2026 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
MKMuhammad Saad Khan
Muhammad Saad Khan
HAHumayou Ahmed
Humayou Ahmed
ESErum Siddiqui
Erum Siddiqui
MKMaliha Khalid
Maliha Khalid
DCDevya Khaim Chandani
Devya Khaim Chandani
MAMuhammad Tarish Abro
Muhammad Tarish Abro
Objective: To evaluate the efficacy and safety of linaclotide in children with functional constipation (FC) by synthesizing evidence from randomized controlled trials (RCTs). Data Sources: A systematic search of PubMed, Scopus, Cochrane Central Register of Controlled Trials, and Google Scholar was conducted from inception through December 2024. The protocol was registered in PROSPERO (CRD420251018285), and the review was performed according to PRISMA guidelines. Study Selection and Data Extraction: RCTs comparing linaclotide with placebo in children (<18 years) with FC were included. Two reviewers independently screened studies, extracted data, and assessed risk of bias using the Cochrane RoB 2 tool. Certainty of evidence was evaluated using the GRADE framework. Data Synthesis: Three RCTs involving 309 pediatric patients were included. Random-effects models demonstrated significant improvements with linaclotide in stool consistency (MD = 0.56, 95% CI, 0.27-0.86; P = .0001) and reduction in straining (MD = −0.26, 95% CI, −0.42 to −0.10; P = .001). No significant effects were observed for spontaneous bowel movement frequency, complete spontaneous bowel movement frequency, or abdominal pain. Treatment-related adverse events were more frequent with linaclotide (relative risk [RR] = 2.93, 95% CI, 1.27-6.77), mainly due to increased diarrhea (RR = 3.81, 95% CI, 1.48-9.82). Relevance to Patient Care and Clinical Practice: Linaclotide may provide symptom relief for selected children with FC, particularly those with hard stools and straining despite conventional therapy. Clinicians should counsel families regarding diarrhea risk and monitor tolerability, while recognizing the limited long-term pediatric evidence. Conclusions: Linaclotide improves stool consistency and reduces straining in pediatric FC but does not consistently improve bowel frequency or global symptom resolution. Its safety profile is generally acceptable, although diarrhea is a notable adverse effect. Further long-term, independently funded trials are needed to define its optimal role in clinical practice.